Pulmonx Corporation (LUNG)
NASDAQ: LUNGHealth CareMedical/Dental InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
LUNG stock chart
Technical analysisKey statistics
All statistics- Market cap
- $111.93M
- EPS (TTM)
- -$1.01
- Dividend yield
- None
- 52-week range
- 1.13 – 3.25
- Day range
- 2.51 – 2.81
- Volume / Avg
- 933.29K / 641.52K
- Beta
- —
- Shares outstanding
- 43.55M
52-week range
LUNG stock today
Shares of Pulmonx (LUNG) finished lower on Nov 20 at $2.57, a drop of 6.20% or $0.17 per share, versus the S&P 500's 3.70% decline. At this level, LUNG sits in the middle of its 52-week range of $1.13 to $3.25: 20.9% below the high, set on Oct 29, 2026 and 127.4% above the low. LUNG is up 16.3% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 78.5%.
Pulmonx has posted a net loss over the last twelve months (EPS of -$1.01), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Pulmonx
Company profilePulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. Glendon E. French
- Headquarters
- Redwood City, CA
- Employees
- 296
- IPO year
- 2020
- Website
- pulmonx.com
Financial highlights
Full financialsIn fiscal 2025, Pulmonx generated $90.5 million in revenue, up 8.0% from fiscal 2024, its 7th consecutive year of revenue growth. Pulmonx reported a net loss of $54.0 million, compared with a loss of $56.4 million a year earlier. Gross margin was 74.2% (up from 74.0%) and operating margin -59.3%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $90.50M | $83.79M | $68.67M | $53.66M | $48.42M |
| Growth | +8.01% | +22.01% | +27.98% | +10.84% | +47.91% |
| Net income | $-54.00M | $-56.39M | $-60.84M | $-58.92M | $-48.66M |
| EPS (diluted) | $-1.33 | $-1.44 | $-1.60 | $-1.59 | $-1.35 |
Analyst forecast
ForecastConsensus (6 analysts)
none
Avg. price target
$4.25+65.37%
- Strong buy 0
- Buy 4
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 27, 2026
- EPS actual vs est.
- $-0.34 vs $-0.26
- Surprise
- -30.77%
LUNG news
All LUNG news- Pulmonx to Participate in the Piper Sandler 38th Annual Healthcare ConferenceGlobeNewswire
- Pulmonx annonce la publication des résultats de l’étude clinique CONVERT sur le système AeriSeal®GlobeNewswire
- Pulmonx gibt Veröffentlichung der CONVERT-Versuchsergebnisse für AeriSeal® System bekanntGlobeNewswire
- Pulmonx Announces Publication of CONVERT Trial Results for AeriSeal® SystemGlobeNewswire
- Pulmonx: 3 Key Takeaways for Long-Term InvestorsNasdaq
- Pulmonx to Participate in Upcoming Investor ConferencesGlobeNewswire
- Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%NasdaqAXGN, GMAB, KIDS, LUNG
- Pulmonx (LUNG) Q3 2026 Earnings Call TranscriptNasdaq
Pulmonx peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| STIMNeuronetics Inc. | 1.25 | +0.81% | $120.60M | vs LUNG |
| APYXApyx Medical Corporation | 2.40 | +0.42% | $101.10M | vs LUNG |
| PYPDPolyPid Ltd. | 6.12 | -6.56% | $129.29M | vs LUNG |
| KRMDKORU Medical Systems Inc. | 3.19 | -7.27% | $138.37M | vs LUNG |
| NYXHNyxoah SA | 0.805 | -7.01% | $81.98M | vs LUNG |
| SKINSkinHealth Systems Inc. Class A | 11.77 | -3.13% | $76.68M | vs LUNG |
| LUCDLucid Diagnostics Inc. | 0.3727 | -3.52% | $72.57M | vs LUNG |
| QTEXQTREX Quantum Ltd. | 1.00 | -10.71% | $70.63M | vs LUNG |
Indexes, lists and sector
Pulmonx stock FAQ
What is Pulmonx's stock price today?
LUNG last traded at $2.57 as of Nov 20, 4:00 PM EST, down 6.20% on the day. Prices are delayed at least 15 minutes.
Who is Pulmonx's CEO?
Mr. Glendon E. French is the chief executive officer of Pulmonx Corporation, which has about 296 employees.
What is the LUNG 52-week high?
The 52-week high for LUNG is $3.25 and the 52-week low is $1.13. The stock is currently 20.9% below its high.